Pilot Study of BCAA on Sleep
Primary Purpose
Sleep Disorder, Traumatic Brain Injury
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Branched Chain Amino Acids
Rice Protein
Microcrystalline Cellulose
Sponsored by
About this trial
This is an interventional treatment trial for Sleep Disorder
Eligibility Criteria
Inclusion Criteria:
- Veteran
- English Speaking
- Accessible via phone
- Sleep problems
Exclusion Criteria:
- Decisional impairment
- Nickel allergy
- Maple syrup urine disease or family history of disease
- Allergy to sucralose
- Currently taking BCAAs
Sites / Locations
- VA Portland Health Care SystemRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Placebo Comparator
Placebo Comparator
Arm Label
BCAAs
Rice Protein
Microcrystalline Cellulose
Arm Description
60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
Rice protein control group: 60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
Placebo control group: 60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
Outcomes
Primary Outcome Measures
Recruitment and retention rates
Number enrolled per month, proportion who complete the protocol
Rates of adherence and treatment fidelity
Proportion of subjects consuming full doses
Assessment process and patient acceptability
Proportion of questionnaires properly completed, actiwatches properly worn, and patient acceptance of protocol
Secondary Outcome Measures
Change in Insomnia Severity Index (ISI)
Measures self-reported insomnia severity; total score range = 0-28 (higher total score = worse insomnia)
Full Information
NCT ID
NCT03990909
First Posted
June 17, 2019
Last Updated
April 4, 2022
Sponsor
Portland VA Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT03990909
Brief Title
Pilot Study of BCAA on Sleep
Official Title
A Pilot Study of Dietary Supplementation With Branched Chain Amino Acids on Sleep
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 1, 2019 (Actual)
Primary Completion Date
August 1, 2024 (Anticipated)
Study Completion Date
August 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Portland VA Medical Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Individuals will be recruited from the VA Portland Health Care System and the community affiliated with Oregon Health & Science University. Traumatic brain injury status will be assessed as a contributing factor. Subjects will be randomized to one of 3 groups (BCAA or one of 2 placebo conditions) and instructed to consume study product twice daily for 21 days. Self-report questionnaires, wrist actigraphy, pressure pain testing, and cognitive function will be assessed pre and post the experimental period.
Detailed Description
The goal of this proposal is to explore the feasibility of, and potential for, dietary supplementation with branched chain amino acids (BCAAs) to effect sleep quality and cognitive function in Veterans. The BCAAs (Leucine, Isoleucine, and Valine) cannot be synthesized endogenously (i.e., they must be obtained through the diet) and are the precursors to >50% of de novo glutamate and GABA synthesis in the brain, which are the primary excitatory and inhibitory neurotransmitters, respectively. Preclinical evidence strongly suggests that dietary BCAA supplementation restores normal sleep-wake patterns and cognitive function following TBI through a restoration in the global cortical excitation:inhibition ratio. BCAA supplementation has been studied extensively in healthy humans and in a variety of disease states, including following TBI, but not yet in Veterans in the chronic phase of recovery from TBI. BCAAs are a commercially available dietary supplement and very well tolerated with minimal side-effects.
Subjects will be randomized in a double-blind fashion through the VA Research Pharmacy to one of three groups: 1) BCAA; 60 g/day in two 30 g doses, 2) rice protein; 60 g/day in two 30 g doses, and 3) placebo; 60 g microcrystalline cellulose in two 30 g doses. BCAA and placebo will be prepared by the VA Research Pharmacy and dispensed in a blinded fashion to Veterans after demonstrating informed consent. Following a ~4-week period of baseline, Veterans will be instructed to consume study product after waking and ~6 hours later, on an empty stomach for a period of up to 21-days. Self-report questionnaires assessing sleep quality, cognitive function, trauma-related symptom severity, and other measures of mental and physical well-being will be administered before and after the experimental period. Wrist actigraphy will be continuously collected over the baseline and the experimental period. Cognitive function will be assessed before and after the experimental period using an established battery of neuropsychological tests (i.e., selected tests from WAIS, D-KEFS, HVLT, COWAT, among others. Pressure pain testing will be conducted before and after the experimental period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Disorder, Traumatic Brain Injury
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
300 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
BCAAs
Arm Type
Experimental
Arm Description
60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
Arm Title
Rice Protein
Arm Type
Placebo Comparator
Arm Description
Rice protein control group: 60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
Arm Title
Microcrystalline Cellulose
Arm Type
Placebo Comparator
Arm Description
Placebo control group: 60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
Intervention Type
Dietary Supplement
Intervention Name(s)
Branched Chain Amino Acids
Other Intervention Name(s)
BCAAs
Intervention Description
60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to21days (42 total drinks).
Intervention Type
Dietary Supplement
Intervention Name(s)
Rice Protein
Intervention Description
60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
Intervention Type
Dietary Supplement
Intervention Name(s)
Microcrystalline Cellulose
Intervention Description
60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
Primary Outcome Measure Information:
Title
Recruitment and retention rates
Description
Number enrolled per month, proportion who complete the protocol
Time Frame
5 weeks
Title
Rates of adherence and treatment fidelity
Description
Proportion of subjects consuming full doses
Time Frame
5 weeks
Title
Assessment process and patient acceptability
Description
Proportion of questionnaires properly completed, actiwatches properly worn, and patient acceptance of protocol
Time Frame
5 weeks
Secondary Outcome Measure Information:
Title
Change in Insomnia Severity Index (ISI)
Description
Measures self-reported insomnia severity; total score range = 0-28 (higher total score = worse insomnia)
Time Frame
Baseline; after 3 weeks of intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
89 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Veteran
English Speaking
Accessible via phone
Sleep problems
Exclusion Criteria:
Decisional impairment
Nickel allergy
Maple syrup urine disease or family history of disease
Allergy to sucralose
Currently taking BCAAs
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Miranda M Lim, MD, PhD
Phone
503-220-8262
Ext
Ext. 57404
Email
lmir@ohsu.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Miranda M Lim, MD, PhD
Organizational Affiliation
Portland VA Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
VA Portland Health Care System
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Miranda M Lim, MD, PhD
Phone
503-220-8262
Ext
57404
Email
lmir@ohsu.edu
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
All non-identifiable data will be made available to qualified researchers on request to the study PI.
IPD Sharing Time Frame
Information will be sent as soon as is practical and will be available as long as the PI is available.
IPD Sharing Access Criteria
Legitimate research agenda, including but not limited to request to double-check presented or published results and novel analyses.
Citations:
PubMed Identifier
35602971
Citation
Elliott JE, Keil AT, Mithani S, Gill JM, O'Neil ME, Cohen AS, Lim MM. Dietary Supplementation With Branched Chain Amino Acids to Improve Sleep in Veterans With Traumatic Brain Injury: A Randomized Double-Blind Placebo-Controlled Pilot and Feasibility Trial. Front Syst Neurosci. 2022 May 4;16:854874. doi: 10.3389/fnsys.2022.854874. eCollection 2022.
Results Reference
derived
Learn more about this trial
Pilot Study of BCAA on Sleep
We'll reach out to this number within 24 hrs